Vitrolife faces a tough 2025, and we expect this to continue during H2 2025, at best, at a fading rate. Vitrolife continues to step up its investments in commercial capacity and sales during a period of softer organic growth. In Q2, the softer areas are part of the APAC regions and the US business. We suspect the US headwind will likely ease before the APAC regions.
LÄS MER
